Accelerate Diagnostics Inc VE/BAIIA

Quel est le VE/BAIIA de Accelerate Diagnostics Inc?

Le VE/BAIIA de Accelerate Diagnostics Inc est N/A

Quelle est la définition de VE/BAIIA?



VE/BAIIA est la valeur de l’entreprise divisée par le bénéfice avant intérêts, impôts, dépréciations et amortissements. Il s'agit d'une mesure du coût d'une action et est plus souvent valable pour des comparaisons entre sociétés que le ratio cours / bénéfice. Il mesure le prix (sous forme de valeur d'entreprise) qu'un investisseur paie au profit des flux de trésorerie de l'entreprise (sous forme de BAIIA).

Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.

Que fait Accelerate Diagnostics Inc?

accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.